Evidence review
Retatrutide Cost: The Two Published Prices We Found
We checked six sellers of retatrutide. Two published a price. Here are both figures, what they buy, and why the silence from the other four matters.
On this page
Retatrutide is the most hyped molecule in this category and one of the hardest to price. We went looking for what it costs across every provider on our own roster that sells it. Six do. On August 12, 2026, two of them published a figure we could read off their own live pages.
That ratio is the most useful thing on this page, so it goes first.
The two published prices
| Provider | Form | Published price |
|---|---|---|
| Concierge MD LA | injection | $399 per month |
| Dr. Gillis Wellness Center | oral / sublingual | from $149 |
Both were read directly off the seller's own live pages on August 12, 2026. Concierge MD LA lists "Retatrutide $399/month" alongside its compounded semaglutide and tirzepatide; Dr. Gillis Wellness Center lists retatrutide among its oral GLP therapies "Available Starting at $149".
Two figures are not a market rate, and we are not going to average them into one. They are also not comparable to each other: one is an injection quoted as a monthly plan, the other an oral product quoted as a starting price, and a starting price is a floor rather than a rate. If you see a "typical retatrutide cost" quoted anywhere as a single number, ask how many sellers it was built from.
What the other four do
One lists retatrutide as a product — branded "RTT (GLP-3)" — without a price in anything a reader can see without starting an intake. Three sell it with no published figure at all: the price arrives at checkout, after a dose is selected, or after a consultation.
That is a much higher rate of price-gating than we see on compounded semaglutide or tirzepatide, where most sellers publish something. The pattern is worth naming rather than shrugging at: the least-established molecule is also the least-priced one in public.
Why the price is not the first question
Retatrutide is not approved by the FDA for anything. It is an investigational triple agonist — GIP, GLP-1 and glucagon — that has completed phase 2 for obesity, where it produced substantial weight loss over 48 weeks1. Phase 2 is not approval, and a phase 2 result is not a license to sell.
So anything you are quoted a price for today is a compounded or research-grade preparation of a drug no regulator has cleared, from a supply chain with no approved reference product to be measured against. Our retatrutide dosage and retatrutide side effects pages set out what is actually known, and the evidence review for athletes and body recomposition covers what the trials do and do not show.
It is also banned in tested sport — see the WADA prohibited list — and if you are buying it as a research chemical rather than through a clinic, where to buy peptides and the legality problem is the page to read first.
What to check before you compare any two quotes
What does the figure buy? A month, four weeks, a vial, or a "starting" dose that rises. The four-week month is common enough in this category that we now check it on every provider.
Is it a plan or a floor? "Starting at" is a floor. It tells you the cheapest rung, not what you will pay at a working dose.
What term does the advertised figure require? A single number on a poster can be the bottom rung of a commitment ladder with the commitment left off. SkinnyRx prices four terms for every product it sells and advertises only the twelve-month one: its "as low as $199/mo" semaglutide is the annual rate, and paying by the month costs $349. Publishing the whole ladder is more than most of this field does; printing only its cheapest rung, with no term beside it, undoes much of the benefit.
Who compounds it, and can you check? With no approved product to compare against, the pharmacy is most of what you are trusting. How to verify a COA is the practical check.
Do the milligrams and the syringe units agree? The FDA has warned specifically about dosing errors on compounded GLP-1s, where the vial is labeled in milligrams and the syringe reads in units2. That risk does not shrink on a molecule with less prescribing experience behind it.
The honest takeaway: of six sellers we checked, two publish a retatrutide price — $399 a month for an injection and from $149 for an oral product — and neither is a market rate. The wider fact is more useful than either figure: the least-established molecule in this category is also the one whose price is hardest to see before you commit, and it is not approved for anything.
Leads our published comparison
CoreAge Rx
From $99/mo
Consult included, no commitment lever, no labs required, dietitian support — on the columns we can source.
If you are drug tested, read this first: These are banned in tested sport, at all times — and a prescription does not change that. Check the compound.
- Pricing
- Not a flat rate
- Pharmacy
- Unnamed network
- Labs
- Not required
Advertising disclosure · both cards are paid partners and we may earn a commission at no extra cost to you — see our disclosure.
Also worth knowing
MyDrHank
Every price it advertises is the twelve-month prepay rung; the month-to-month rate renders on no page.
- Pricing
- Prepay required
- Pharmacy
- Not disclosed
- Labs
- Not required
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37366315/
- U.S. Food and Drug Administration (2024). FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. FDA Drug Safety Communication. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Retatrutide for Athletes: Triple-Agonist Recomp Evidence (& WADA Status)
Retatrutide drove ~24% weight loss in a Phase 2 obesity trial — but it's not FDA-approved and is WADA-prohibited. An honest, citation-first read for athletes.
ReadRetatrutide Side Effects: What the Trials Actually Report
Retatrutide has no FDA label, so there's no official side-effect list — only trial disclosures. What Phase 2, Phase 3, and a new 2026 signal actually show.
ReadRetatrutide Dosage: What Trials Actually Used (There's No Approved Dose)
Retatrutide has no FDA-approved dose — it's still in Phase 3 trials. Here's exactly what dose, titration schedule, and results the actual trials used.
ReadRetatrutide vs Tirzepatide: One Is Approved, One Is Not
Three receptors versus two, and Phase 2 versus Phase 3 and approval. The comparison people want is efficacy; the one that matters is evidence stage.
ReadSemaglutide Cost: The Same Molecule, Priced Four Ways
Ozempic and Wegovy list near $1,000-$1,349 a month, Novo sells direct from $149, and compounded telehealth ran $125-$349 in our August 2026 checks. The map.
ReadTirzepatide Cost: What a Month Really Runs
Zepbound self-pay runs $299 to $699 a month by dose. Compounded tirzepatide medians about $289 in our checks — most advertised prices hide a commitment lever.
Read